Pelacarsen didn’t protect heart health despite lowering levels of a protein particle, “Lp(a),” in a large clinical trial — a ...
The drugmaker is leaning on a better side effect profile compared to drugs from J&J, Pfizer and Regeneron as it pushes ...
Deals with Chinese drugmakers are continuing at a steady pace, while two mid-cap biotechs' stock prices took a tumble this ...
Superluminal Medicines banked $60 million in funding to support development of a drug designed to work similarly to — but ...
With its latest foray into China, GSK acquired rights from Hutchmed to an “antibody-targeted therapy conjugate” impacting two ...
The failure of what was once considered a potential blockbuster therapy represents a major setback in a tough-to-treat ...
A new data cut of a trial pitting ivonescimab, a bispecific antibody, against Merck’s Keytruda showed the new drug helped ...
CAR-T’s commercial challenge is making thousands of patient-specific manufacturing runs behave like one reliable system. "In ...
Wall Street analysts believe that a more cautious approach to manufacturing, study enrollment and side effect management ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results